Description

Beinaglutide is a recombinant human glucagon-like peptide-1 (GLP-1), identical in sequence to native human GLP-1 (7-36). Designed as a short-acting GLP-1 receptor agonist, it exerts potent, dose-dependent effects on glucose metabolism, satiety, and body weight regulation. In animal models, Beinaglutide administered subcutaneously reduces food intake, slows gastric emptying, improves insulin sensitivity, and facilitates significant weight loss. In randomized clinical trials, it continues to align with GLP-1RA profiles, showing benefits in body weight, BMI, waist circumference, triglycerides, and systolic blood pressure—particularly at lower doses and longer durations of treatment. Manufactured to a high standard (purity ?99.74%) and produced under GMP conditions, Beinaglutide is a reliable and reproducible tool for metabolic and endocrinology research.

Product Category

Incretin-Based Metabolic Peptides — biologically active peptides targeting GLP-1 receptors, widely used in studies of obesity, diabetes, and cardiometabolic regulation.

Product Specifications

Mechanism of Action & Research Applications

Beinaglutide acts by activating GLP-1 receptors, leading to enhanced insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduced appetite. These mechanisms collectively drive improved glucose regulation and weight loss. Research models show notable reductions in body weight, BMI, waist circumference, triglyceride levels, and systolic blood pressure, especially with long-duration treatment at lower doses. Unlike long-acting GLP-1 analogs, Beinaglutide’s shorter action profile offers flexibility for examining acute-phase receptor dynamics, signaling, and metabolic outcomes across preclinical and clinical translational studies.

Side Effects (For Research Context Only)

In both animal and clinical settings, Beinaglutide administration has been associated with nausea, vomiting, palpitations, headache, and dizziness—particularly at higher doses. These side effects align with those seen for other GLP-1 receptor agonists but generally do not lead to serious adverse events. Hypoglycemia, fatigue, diarrhea, and serious complications remained comparable to control groups in clinical trials, underscoring an acceptable safety profile for research use.

Logistics Transportation

All packages are shipped with full insurance to ensure timely and secure delivery. We offer 100% compensation for any lost, detained, or damaged items during transit.

Disclaimer

Beinaglutide is strictly for laboratory research use only. It is not approved for clinical, therapeutic, veterinary, or diagnostic applications.